Crane Harbor Acquisition Corp. II - Class A Ordinary Shares (CRAN)
Live price chart, market sentiment, and community perspectives for Crane Harbor Acquisition Corp. II (NASDAQ: CRAN).
Live price chart, market sentiment, and community perspectives for Crane Harbor Acquisition Corp. II (NASDAQ: CRAN).
On our desk, we are treating Crane Harbor Acquisition Corp. II as a textbook pre-combination SPAC. Trading consistently around $10.14, it hugs its baseline trust value nicely between the $9.63 support and $10.65 resistance tiers. While a single analyst consensus assigns it a Sell rating with a $0.00 price target, that is largely typical boilerplate for blank check entities lacking an active business combination target. We are watching the recent growth in short interest closely to see if retail momentum can trigger any minor squeezes within this tight range.
Looking at the quantitative models from CirclFi, CRAN scores a mediocre 5.0/10 on the Quality of Company framework. Three out of three valuation models project zero upside at the current $10.14 market price, indicating that mixed operational fundamentals are fully priced in. With zero revenue and operating expenses running around $246K in Q1 2026, the company functions entirely as a cash shell waiting for a merger catalyst. Do not expect any fundamental alpha until a definitive acquisition announcement hits the wire.
From a settlement and clearing perspective, the FTD data for CRAN shows very low structural risk. SEC data from February 2026 recorded just 216 failed-to-deliver shares, representing roughly 0.41% of average daily volume. Even with short interest seeing a noticeable upward tick according to recent filings, the clearing mechanics remain clean, and counterparty delivery friction is practically non-existent. This ensures smooth execution for anyone entering or exiting positions near the $10.15 mark.
Reviewing the balance sheet and quarterly filings, net income of $2.81M in Q1 2026 primarily reflects interest income generated from trust account holdings rather than core business operations. Operating expenses remain modest but are scaling upward as legal and administrative overhead accumulates. Until management announces a target merger or business combination, CRAN will continue to behave strictly as a fixed-income proxy with an embedded equity option on a future deal.
As a risk manager tracking micro-cap blank checks, I find CRAN's lack of operating revenue entirely expected for an SIC 6770 entity. Total assets consist predominantly of cash and short-term holdings, shielding the equity from operational cash-burn hazards typical of early-stage operating companies, though administrative expenses like the $246.31K logged in Q1 2026 steadily eat away at the trust cushion over time. Holding steady at $10.14 with minimal volume underscores that the market is essentially parking capital here pending corporate developments.
Explore plasma cleansing, somatic organ swaps, and BCI.